60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026 [Yahoo! Finance]
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its price target lowered by analysts at Ascendiant Capital Markets from $3.00 to $2.80. They now have a "buy" rating on the stock.
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine